AVEO PHARMACEUTICALS INC (AVEO)
US0535883070 - Common Stock
Taking everything into account, AVEO scores 3 out of 10 in our fundamental rating. AVEO was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of AVEO have multiple concerns. AVEO is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
AVEO had negative earnings in the past year.
AVEO had a negative operating cash flow in the past year.
AVEO had negative earnings in 4 of the past 5 years.
AVEO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The profitability ratios for AVEO are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 87.81%, AVEO belongs to the best of the industry, outperforming 91.08% of the companies in the same industry.
AVEO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AVEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVEO has more shares outstanding
AVEO has a worse debt/assets ratio than last year.
2.2 Solvency
AVEO has an Altman-Z score of -4.48. This is a bad value and indicates that AVEO is not financially healthy and even has some risk of bankruptcy.
AVEO's Altman-Z score of -4.48 is on the low side compared to the rest of the industry. AVEO is outperformed by 68.86% of its industry peers.
AVEO has a Debt/Equity ratio of 0.94. This is a neutral value indicating AVEO is somewhat dependend on debt financing.
AVEO has a Debt to Equity ratio of 0.94. This is amonst the worse of the industry: AVEO underperforms 82.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.48 |
ROIC/WACCN/A
WACC9.35%
2.3 Liquidity
A Current Ratio of 2.37 indicates that AVEO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.37, AVEO is doing worse than 78.87% of the companies in the same industry.
A Quick Ratio of 2.35 indicates that AVEO has no problem at all paying its short term obligations.
AVEO has a worse Quick ratio (2.35) than 77.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.37 | ||
| Quick Ratio | 2.35 |
3. Growth
3.1 Past
AVEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
AVEO shows a strong growth in Revenue. In the last year, the Revenue has grown by 269.46%.
AVEO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 76.06% yearly.
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q70%
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Revenue growth Q2Q100.68%
3.2 Future
Based on estimates for the next years, AVEO will show a very strong growth in Earnings Per Share. The EPS will grow by 40.39% on average per year.
The Revenue is expected to grow by 75.28% on average over the next years. This is a very strong growth
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AVEO. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 27.40, AVEO can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AVEO indicates a rather cheap valuation: AVEO is cheaper than 96.09% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.88, AVEO is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.4 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AVEO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVEO's earnings are expected to grow with 40.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.26%
EPS Next 3Y40.39%
5. Dividend
5.1 Amount
AVEO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVEO PHARMACEUTICALS INC
NASDAQ:AVEO (1/19/2023, 7:09:51 PM)
After market: 15 0 (0%)15
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap521.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.4 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.81% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.93
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.37 | ||
| Quick Ratio | 2.35 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y59.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y